Citi Appointed as Depositary Bank for Freeline’s ADR Programme
Retrieved on:
Friday, August 14, 2020
Citi, acting through Citibank N.A., has been appointed by Freeline Therapeutics Holdings plc (Freeline), a clinical-stage gene therapy company, to act as depositary bank for its American Depositary Receipt (ADR) programme.
Key Points:
- Citi, acting through Citibank N.A., has been appointed by Freeline Therapeutics Holdings plc (Freeline), a clinical-stage gene therapy company, to act as depositary bank for its American Depositary Receipt (ADR) programme.
- Freelines American Depositary Shares (ADS) trade on The Nasdaq Global Select Market under the symbol FRLN.
- Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions.
- Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi
View source version on businesswire.com: https://www.businesswire.com/news/home/20200814005361/en/